JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Enhanced IL36RN Expression and Its Association With Immune Microenvironment Predicts Poor Prognosis in Gastric Cancer

  • 0Clinical and Translational Research Center, Affiliated Hospital of Nantong University and Medical School of Nantong University, Nantong, Jiangsu, China.
Cancer Medicine +

|

May 10, 2025

|

May 10, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Interleukin-36 receptor antagonist (IL36RN) is upregulated in gastric cancer (GC), promoting tumor growth and invasion. Targeting IL36RN may offer new strategies for GC treatment and immunotherapy.

Area Of Science

  • Oncology
  • Immunology
  • Genomics

Background

  • Gastric cancer (GC) is a significant global health challenge requiring novel therapeutic targets.
  • Understanding the tumor microenvironment (TME) is crucial for improving GC patient outcomes.

Purpose Of The Study

  • To investigate the role of IL36RN in gastric cancer.
  • To evaluate IL36RN as a prognostic biomarker and therapeutic target in GC.

Main Methods

  • Analysis of IL36RN mRNA expression in GC tissues using The Cancer Genome Atlas (TCGA) dataset.
  • Bioinformatics, cellular models, and tissue microarrays were utilized to study IL36RN function and TME interactions.
  • Functional assays assessed the impact of IL36RN silencing on GC cell behavior.

Main Results

  • IL36RN expression was significantly higher in GC tissues compared to normal tissues.
  • Upregulated IL36RN correlated with poorer survival outcomes in GC patients.
  • Silencing IL36RN inhibited GC cell proliferation and invasion.
  • Elevated IL36RN levels were associated with increased CD8+ T cell infiltration in the TME.
  • IL36RN independently predicted prognosis in GC.

Conclusions

  • IL36RN is a potential prognostic biomarker for gastric cancer.
  • IL36RN represents a promising therapeutic target for precision oncology and immunotherapy in GC.

Keywords: